[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments].

Wiewrodt, R; Serke, M; Grohé, C; Brückl, W

[Employing tyrosine kinase inhibitors in the first line treatment of EGFR-positive metastatic NSCLC - state of the art and recent developments]. / Der Einsatz von Tyrosinkinase-Inhibitoren bei aktivierenden EGFR-Mutationen in der Erstlinientherapie beim fortgeschrittenen nicht-kleinzelligen Lungenkarzinom (NSCLC) - aktueller Stand und Entwicklungen.

Wiewrodt, R; Serke, M; Grohé, C; Brückl, W.

Affiliation

Wiewrodt R; Klinik und Poliklinik für Innere Medizin A (Hämatologie, Onkologie und Pneumologie) Universitätsklinikum Münster.

Pneumologie ; 67(9): 494-501, 2013 Sep.

Article in De | MEDLINE | ID: mdl-24006195

Subject(s)

Antineoplastic Agents/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Carcinoma, Non-Small-Cell Lung/secondary; Lung Neoplasms/drug therapy; Lung Neoplasms/secondary; Protein Kinase Inhibitors/therapeutic use; Protein-Tyrosine Kinases/antagonists & inhibitors; Antibodies, Monoclonal/therapeutic use; Carcinoma, Non-Small-Cell Lung/metabolism; ErbB Receptors/antagonists & inhibitors; Evidence-Based Medicine; Humans; Lung Neoplasms/metabolism; Treatment Outcome

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Protein-Tyrosine Kinases / Carcinoma, Non-Small-Cell Lung / Protein Kinase Inhibitors / Lung Neoplasms / Antineoplastic Agents Aspects: Patient_preference Limits: Humans Language: De Journal: Pneumologie Year: 2013 Document type: Article Country of publication: Germany

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google